| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10899802 | Cancer Letters | 2014 | 5 Pages |
Abstract
The result of this review shows benefit of these target drugs in tumor burden, increase progression-free and overall survival and improvement the quality of life compared with previous toxic immunotherapy, although complete response remains rare.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jane Mattei, Rodrigo Donalisio da Silva, David Sehrt, Wilson R. Molina, Fernando J. Kim,